TY - JOUR
T1 - The CDKN2 gene alterations in various types of adult T-cell leukaemia
AU - Uchida, Toshiki
AU - Kinoshita, Tomohiro
AU - Watanabe, Takashi
AU - Nagai, Hirokazu
AU - Murate, Takashi
AU - Saito, Hidehiko
AU - Hotta, Tomomitsu
PY - 1996
Y1 - 1996
N2 - The CDKN2 gene, encoding the cyclin-dependent kinase-4 inhibitor p16, is a putative tumour-suppressor gene because it is frequently altered in many malignant tumours. We analysed the CDKN2 gene in 44 cases of adult T-cell leukaemia (ATL) by Southern blot analysis, polymerase chain reaction-mediated single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing. Southern blot analysis detected a homozygous deletion of the CDKN2 gene in 5/44 patients (11.4%). Mutational analysis by the PCR-SSCP method and direct sequencing showed one nonsense mutation at codon 72 (nucleotide 232), and two missense mutations at codon 43 (nucleotide 146) and codon 97 (nucleotide 309, 3/44, 6.8%). Therefore we found changes in the CDKN2 gene, including point mutations, in 18.2% of the patients with ATL. Interestingly, most of these patients had acute type ATL. Our results suggest that the CDKN2 gene is inactivated not only by homozygous deletion but also by point mutation, and these alterations contribute to the aggressiveness of ATL.
AB - The CDKN2 gene, encoding the cyclin-dependent kinase-4 inhibitor p16, is a putative tumour-suppressor gene because it is frequently altered in many malignant tumours. We analysed the CDKN2 gene in 44 cases of adult T-cell leukaemia (ATL) by Southern blot analysis, polymerase chain reaction-mediated single-strand conformation polymorphism (PCR-SSCP) analysis, and direct sequencing. Southern blot analysis detected a homozygous deletion of the CDKN2 gene in 5/44 patients (11.4%). Mutational analysis by the PCR-SSCP method and direct sequencing showed one nonsense mutation at codon 72 (nucleotide 232), and two missense mutations at codon 43 (nucleotide 146) and codon 97 (nucleotide 309, 3/44, 6.8%). Therefore we found changes in the CDKN2 gene, including point mutations, in 18.2% of the patients with ATL. Interestingly, most of these patients had acute type ATL. Our results suggest that the CDKN2 gene is inactivated not only by homozygous deletion but also by point mutation, and these alterations contribute to the aggressiveness of ATL.
UR - http://www.scopus.com/inward/record.url?scp=0029758396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029758396&partnerID=8YFLogxK
U2 - 10.1046/j.1365-2141.1996.d01-1841.x
DO - 10.1046/j.1365-2141.1996.d01-1841.x
M3 - Article
C2 - 8826890
AN - SCOPUS:0029758396
SN - 0007-1048
VL - 94
SP - 665
EP - 670
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 4
ER -